BLADDER CANCER

This study tested a virus-based treatment called CG0070 for people with a high-grade type of bladder cancer that did not respond to standard therapy (BCG) and who chose not to have their bladder removed. The goal was to see if the treatment could control the cancer and reduce the…

This early-phase study tests a treatment called TBI-1301 for people with advanced solid tumors (like sarcoma, melanoma, or ovarian cancer) that have not responded to other therapies. The treatment uses a patient's own immune cells, which are genetically modified in a lab to bette…

This study tests whether a virus-based treatment called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from returning after surgery. About 367 participants will either receive the treatment or be monitored. The goal is to see if the therapy extends th…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (gemcitabine and cisplatin) is safe and effective for people with advanced bladder cancer. About 54 adults with metastatic or muscle-invasive bladder cancer will receive the combination. …

This study tests whether a precise type of radiation called SBRT can restore the effectiveness of immunotherapy drugs in people with metastatic cancer that has started to grow again. About 69 adults with cancers such as melanoma, lung, bladder, kidney, or head/neck cancer will re…

This study tests whether adding the experimental drug visugromab to standard immunotherapy can help shrink muscle-invasive bladder cancer before surgery. About 31 adults who cannot or choose not to receive cisplatin chemotherapy will receive the combination before having their bl…

This study compares two drugs, mannitol and nitroglycerin, given during robotic prostate or bladder cancer surgery to see if they can prevent acute kidney injury. The surgery uses gas to inflate the belly, which can reduce blood flow to the kidneys. The trial includes 90 adults w…

This study tests a pill called erdafitinib in people whose bladder cancer has come back after standard treatments like BCG or chemotherapy. Only patients with a specific gene change (FGFR3 mutation) in their tumor can join. The goal is to see if the pill can shrink or eliminate t…

This study tests an experimental drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the safest dose and see if the drug can shrink tumors. About 310 adults whose cancer has not respon…

This study tests an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors (e.g., ovarian, breast, prostate, lung cancer). The goal is to see if the drug is safe and can shrink tumors when given alone or with other anti-cancer medicines. About 70…

This study tests whether giving immunotherapy drugs (nivolumab alone or with ipilimumab) before bladder cancer surgery is safe and does not delay the operation. The goal is to shrink the tumor, making surgery more successful. It involves 52 adults with muscle-invasive bladder can…

This study tests whether adding urelumab to nivolumab (both immunotherapy drugs) before bladder removal surgery improves the immune response against muscle-invasive bladder cancer. It includes 15 patients who either cannot receive standard chemotherapy due to health reasons or ch…

This trial tests whether giving a special BCG treatment directly into the bladder, followed by chemotherapy and immunotherapy, can make muscle-invasive bladder cancer disappear before surgery. The goal is to increase the chance of a complete response, so patients might avoid havi…

This study tests whether starting immunotherapy early, based on a sensitive blood test that finds tumor DNA, can better control metastatic bladder cancer after bladder removal surgery. About 154 adults with signs of cancer in their blood, with or without visible tumors on scans, …

This early-stage study tests a combination of two drugs—romidepsin and durvalumab—given directly into the bladder for people with muscle-invasive bladder cancer who cannot take standard chemotherapy. The goal is to see if the treatment is safe and can shrink or eliminate tumors b…

This study tests whether the drug atezolizumab can help keep bladder cancer from coming back after chemo-radiation therapy. It is for people with muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. The goal is to control the disease and avoid re…

This study looks at how safe and effective a new robotic surgery system (Medtronic Hugo) is for removing cancers of the prostate, bladder, or kidney. About 144 adults who need these surgeries will take part. The main goal is to see if the surgery can be completed without switchin…

This study tests a new drug, UGN-103, placed directly into the bladder to treat a common type of bladder cancer that hasn't spread deep into the bladder wall. About 99 people with low-grade, intermediate-risk bladder cancer will receive the treatment. The main goal is to see if t…

This study tests a drug called ado-trastuzumab emtansine (T-DM1) in 131 adults with advanced solid tumors that have a specific change in the HER2 gene. The goal is to see how well the drug shrinks or controls the cancer. Participants must have certain HER2 mutations or amplificat…

This early-phase study tests the safety of a drug called UGN-201 in 10 people with bladder cancer who are scheduled to have their bladder removed (cystectomy). The drug is given before surgery to see if it is safe and to explore whether it can shrink the tumor. Researchers also l…

This early-phase study tests the safety of a new drug called AB598, given alone or with other treatments, in about 40 people with advanced solid tumors (e.g., lung, bladder, breast, or ovarian cancer). The main goal is to see if the drug is safe and tolerable. Participants must h…

This study tests whether adding the immunotherapy drug pembrolizumab to standard BCG treatment can keep high-risk bladder cancer from coming back. About 45 people with early-stage but aggressive bladder cancer will receive both drugs as their first treatment. The goal is to see i…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy helps people with bladder cancer that has spread to nearby lymph nodes. About 60 participants will receive either chemo alone or chemo plus durvalumab, followed by maintenance durvalumab fo…

This study tests a combination of two chemotherapy drugs, gemcitabine and docetaxel, given directly into the bladder for people with early-stage bladder cancer who have not received standard BCG therapy. The goal is to see if this treatment can clear the cancer and keep it from c…

This study tests a new combination treatment for people with a type of bladder cancer that has not responded to standard therapy. The treatment involves putting two drugs directly into the bladder through a catheter. The goal is to see if this approach can eliminate the cancer or…

This early-phase study tests a new drug, AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment for people with advanced solid tumors that have stopped responding to standard therapies. The main goal is to find the safest dose and check for…

This study tests whether adding the drug durvalumab to standard treatment (surgery, chemotherapy, and radiation) helps prevent bladder cancer from coming back. About 82 people with muscle-invasive bladder cancer that hasn't spread will take part. The goal is to see if the combina…

This study tested a combination of four chemotherapy drugs (5-FU, leucovorin, gemcitabine, and cisplatin) in 46 people with advanced or spreading bladder or urachal cancer. The goal was to see if the combo could shrink tumors or stop them from growing. The trial is no longer recr…

This early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors, including bladder, breast, lung, and other cancers. The goal is to find a safe and effective dose and see if the drug can shrink tumors. About 490 participants will take p…

This study tests whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can keep bladder cancer from coming back after surgery. About 230 people with high-risk muscle-invasive bladder cancer will receive either the vaccine plus immunotherapy o…

This study tests whether adding the drug nivolumab after standard chemo-radiation can help keep bladder cancer from coming back. About 200 adults with localized muscle-invasive bladder cancer who cannot have bladder removal surgery are taking part. The main goal is to see how man…

This early-phase trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 120 people with various canc…

This study is testing whether two new treatments work better than the current standard therapy for high-risk bladder cancer that hasn't spread into the muscle wall. Researchers are comparing a new drug delivery system called TAR-200 (with or without an immunotherapy drug called c…

This study looks at a urine test called Bladder CARE Assay to see if it can accurately detect bladder cancer in people whose standard tests (cystoscopy or cytology) were not clear. About 80 adults with suspicious but inconclusive results will provide a urine sample before their n…

This study is testing a new urine test that looks for specific markers of bladder cancer. The goal is to catch the disease early in people who are at high risk, such as those over 50 with a heavy smoking history. Researchers will follow 173 participants for up to 4 years to see h…

This study looks at whether a new screening method using PHI blood test and mp-MRI scans can find prostate cancer earlier in men with DNA repair gene (DRG) mutations. Current screening often misses aggressive cancers in these men. The goal is to catch more cancers early, when the…

This study is testing a new urine test that looks for specific markers of bladder cancer. It involves 450 adults who have visible blood in their urine. The goal is to see if this simple test can accurately detect bladder cancer without needing a more invasive camera procedure cal…

This study compares two imaging methods—CT urography and IV urography—to see how well they show bladder and urinary tract tumors. About 133 people with bladder cancer will get both scans as part of their routine care. The goal is to find out if the newer CT scan alone is good eno…

This study looks at whether giving whole brain radiation to people with small cell bladder cancer can lower their risk of developing brain tumors. The trial includes 31 patients whose cancer had spread but responded well to chemotherapy. Researchers will track how many patients s…

This study looks at whether JING SI HERBAL TEA can help reduce urinary symptoms like pain or urgency that often occur after intravesical therapy for bladder cancer. About 100 adults with bladder cancer who have received this treatment will drink the tea and report changes in thei…

This study looks at the chromosomes of people with bladder cancer to find patterns that may help explain how the disease starts and grows. No treatments or drugs are being tested. Up to 5,000 participants will provide samples for lab analysis.

This study looks at what information and support people with bladder cancer need after having their bladder removed (cystectomy). Researchers will follow 200 Swedish-speaking adults to understand their changing needs over time. The goal is to learn how to better help patients man…

This study looks at how bladder cancer treatments affect patients' quality of life over time. Researchers will ask 2000 people in Denmark about their symptoms and daily life after treatment. The goal is to understand which late effects matter most and who is at risk.

This study creates a large registry of over 3,500 people, including those with and without urothelial cancer (bladder, ureter, or kidney pelvis cancer). Researchers collect saliva samples and health information to find genetic markers and risk factors linked to the disease. The g…

This study collects tumor tissue from about 416 people with various advanced cancers to develop and train a new diagnostic platform called Elephas. The goal is to see how accurately the platform can predict whether a patient will respond to immunotherapy, compared to standard met…

This study gives a targeted drug called abemaciclib to 20 people with bladder cancer who cannot take standard chemotherapy. The drug is taken for a short time before the bladder is removed surgically. Researchers compare tumor samples taken before and after the drug to see how it…

This study looks at whether wearable fitness trackers can help doctors spot early warning signs of complications in people recovering from bladder removal surgery. About 50 participants will wear a Fitbit and answer daily questions on their phone before and after surgery. Researc…

This study collects DNA from over 21,000 people with different cancers (like breast, colon, and lung) in New York. Researchers will look for inherited gene changes that might be linked to cancer. The goal is to find clues for future studies, not to test a treatment.

This early-phase study tests a special PET scan agent (18F-fluciclovine) to see if it can more accurately show how far muscle-invasive bladder cancer has spread compared to standard CT or MRI scans. Sixteen adults with bladder cancer scheduled for bladder removal surgery will rec…

This study follows 600 people with non-muscle invasive bladder cancer to see how lifestyle choices like smoking and body weight affect the chance of cancer coming back. Researchers will track these habits over time and compare them to recurrence rates. The goal is to understand w…

This study compares two treatments for a type of bladder cancer that keeps coming back: medication placed directly into the bladder versus surgery to remove the bladder. Researchers want to see which option gives patients a better quality of life and overall experience. About 570…

This study looks at the financial burden (called financial toxicity) that people face after having robotic surgery for prostate, bladder, or kidney cancer. Researchers will ask 120 patients to fill out questionnaires about their expenses, travel costs, and support needs. The goal…

This study gave 20 people with muscle-invasive bladder cancer either pembrolizumab alone or with entinostat before their scheduled surgery. The goal was to measure changes in immune-related genes in the tumor, not to cure the disease. Participants were people who couldn't or woul…

This study aims to find out why some people are more likely to develop bladder cancer. Researchers will compare the genes and lifestyle habits of people with and without bladder cancer. The goal is to identify factors that increase risk, such as how the body processes tobacco che…

This study looks at two blood-thinning medicines (apixaban and enoxaparin) given to bladder cancer patients after bladder removal surgery. The goal is to see which drug patients are more likely to take as prescribed, which they prefer, and how much each costs them. About 90 adult…

This study tests a new system that helps doctors better understand the needs of older adults with cancer. The system combines checks on aging, mental health, lifestyle, and social factors. About 35 patients aged 65 and older will try it during their first cancer visit. The goal i…